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Introduction
The disease phenotypes of Helicobacter pylori infec-
tion include gastritis (80–85%), peptic ulcer (10–15%),
gastric adenocarcinoma (1–2%), and gastric mucosa-
associated lymphoid tissue lymphoma (< 0.01%).
Currently, eradication of H. pylori can decrease the re-
currence of peptic ulcer and gastric mucosa-associated
lymphoid tissue lymphoma, potentially prevent the
development of gastric cancer, and be beneficial in a
certain number of cases of functional dyspepsia.1 The
variable clinical outcomes of H. pylori infection are
attributed to the variation in extent and severity of gas-
tric inflammation, with resultant differences in gastric
acid secretion.2,3 A complex interaction of host and
microbes that leads to chronological changes in pat-
tern of gastritis and gastric acid secretion is the gateway
to understanding the pathogenesis of H. pylori-related
gastroduodenal disorders. Age at infection, environ-
mental cofactors (e.g. nutrition), host genetic status,
and microbial virulence are factors that influence the
above interaction.4,5
To date, the real role of chronic H. pylori infection
in patients with cirrhosis and upper gastrointestinal
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bleeding is still uncertain. However, a high prevalence
of H. pylori in patients with liver cirrhosis has been
found.6–10 Eradication of H. pylori is very efficacious in
the treatment of various upper gastrointestinal dis-
eases.11 Current strategies for the cure of H. pylori in-
fection include triple therapy with a proton pump
inhibitor, amoxicillin, and clarithromycin or metroni-
dazole,12 but the development of resistance of H. pylori
to the latter 2 drugs has been reported.13 Therefore,
an understanding of the determinants of the success
or failure of attempts to cure H. pylori infection with
triple therapy is clinically important.
Hepatic drug oxidation is a major source of inter-
individual variations in pharmacokinetics and therapeu-
tic response. The discovery of polymorphic oxidative
metabolism of S-mephenytoin 4-hydroxylation via
CYP2C19 has opened up a new discipline in the study
of drug metabolism.14,15 Proton pump inhibitors such
as omeprazole and rabeprazole are widely used as
acid-inhibitory agents for the treatment of acid-related
diseases (e.g. peptic ulcer, and gastroesophageal reflux
disease).16 Moreover, a CYP2C19 genotype-dependent
difference in rabeprazole pharmacodynamics has been
demonstrated.17 On the basis of this assumption, we
prospectively studied whether or not differences in
CYP2C19 genotype status would affect cure rates for
H. pylori infection and peptic ulcer in patients with
cirrhosis who received triple therapy with rabeprazole,
amoxicillin and clarithromycin.
Methods
Adult patients diagnosed with cirrhosis between Jan-
uary 2002 and December 2006 were evaluated. In-
clusion criteria were: (1) no known previous bleeding
from the upper gastrointestinal tract; (2) cirrhosis with
no other disease (e.g. cancer) that reduced life expec-
tancy; and (3) cirrhosis with no known antibiotic re-
sistance, especially to clarithromycin, or very poor
compliance. Ten patients with bleeding diathesis, chronic
obstructive lung disease, heart disease or renal disease
were excluded from the study.
Functional hepatic reserve was classified according
to the Pugh-modified Child’s classification. The patients
in Child–Pugh class A were defined as having com-
pensated cirrhosis; the patients in Child–Pugh classes
B and C were defined as having decompensated dis-
ease. The study sample consisted of 95 patients with
cirrhosis and gastric ulcer (n = 48) or duodenal ulcer
(n = 47). Seventy-one patients were male, and 24
were female, with a mean age (± standard deviation) of
46.5 ± 6.0 years. All were positive for H. pylori on
rapid urease testing. For the treatment of H. pylori-
infected active peptic ulcers, all patients were assigned
to an open-label 2-week course of oral amoxicillin
1,000 mg twice daily (b.i.d.), clarithromycin 500 mg
b.i.d., and rabeprazole 20 mg b.i.d.
Patient adherence to therapy and occurrence of
side effects were assessed by interviews. Gastroduo-
denoscopy and determination of H. pylori infection
were done before and 3 months after treatment. En-
doscopists were blinded to patient treatment status
and genotypes. Written informed consent was obtained
from each patient before the study began, and our
protocol was approved by the hospital’s Human Insti-
tutional Review Board. During gastroduodenoscopy,
we performed routine inspection of the upper gastroin-
testinal tract, and biopsy specimens were taken from
the antrum for rapid urease testing.18 All patients also
underwent 13C-urea breath testing. Failure to cure 
H. pylori infection was defined as a positive result on
any of these tests.
Genotyping procedures that identified wild-type
(wt) CYP2C19 gene and the 2 mutated alleles,
CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4,
were performed by polymerase chain reaction (PCR)
and restriction fragment length polymorphism analy-
sis, as described by de Morais and colleagues,19,20 with
minor modifications as described by Kubota and co-
workers.21 Extracted genomic DNA was dissolved in
distilled water (DNA solution). Genotyping procedures
for identifying the wt CYP2C19 gene and the 2 mutated
alleles, CYP2C19m1 and CYP2C19m2, were carried
out by PCR-restriction fragment length polymorphism
analysis with allele-specific primers. Genomic DNA
(200 ng) was amplified in 1 × PCR buffer [67 mM
Tris-HCl, pH 8.8, 17 mM (NH4)2SO4, 10 mM β-
mercaptoethanol, 7 μM EDTA, 0.2 mg/mL bovine
serum albumin] that contained 50 μM dATP, dCTP,
dGTP and dTTP, 0.25 μM PCR primers, 2.5 U
AmpliTaq DNA polymerase (Perkin Elmer Cetus,
Norwalk, CT, USA), and 3.0 mM MgCl2. The forward
primer (5-TATTATTATCTGTTAACTAATATGA-3)
annealed in exon 3, 78 base pairs (bp) upstream from
the exon 4/intron 3 junction, and the reverse primer
(5-ACTTCAGGGCTTGGTCAATA-3) annealed in
intron 4, 88 bp downstream from the exon 4/intron
4 junction. Amplification was performed using a
Perkin Elmer thermocycler, for 35 cycles of denatura-
tion at 94°C for 1 minute, annealing at 53°C for 30
seconds, and extension at 72°C for 30 seconds. An
initial denaturation step at 94°C for 5 minutes and a
final extension step at 72°C for 5 minutes were also
performed. For sequencing, the PCR product was puri-
fied using Microcon and Amicon (Millipore Corp.,
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Billerica, MA, USA) columns, and an aliquot was used
in the cycle sequencing reaction that used fluorescence-
tagged dye terminators (PRISM; Applied Biosystems
Inc., Foster City, CA, USA), the same forward primer
used in the PCR, and an automated sequencer (Applied
Biosystems Inc.).
For detection of CYP2C19m1 in exon 5 and
CYP2C19m2 in exon 4, genomic DNA (200 ng) was
amplified in PCR buffer (50 μL) that contained
10 mmol/L Tris-HCl (pH 8.3), 50 mmol/L KCl,
0.01% gelatin dNTP mix (dATP, dCTP, dGPT and
dTTP; 200 μmol/L final concentration; Takara Shuzo
Co. Ltd., Shiga, Japan), 0.2 μmol/L PCR primers,
1.25 U AmpliTaq DNA polymerase (Hoffmann-
La Roche Ltd., Basel, Switzerland), and 1.5 mmol/L
MgCl2. Amplification was carried out with an auto-
matic thermal cycler (DNA Thermal Cycler PJ 2000;
Perkin Elmer) for 40 cycles of denaturation at 94°C
for 1 minute, annealing at 57°C for 1 minute, and exten-
sion at 72°C for 2 minutes. An initial denaturation step
at 94°C for 5 minutes and a final extension step at 72°C
for 5 minutes were also performed. Restriction enzyme
cleavage was conducted at 37°C for 1 hour after the
addition of 25 U MspI for CYP2C19m1 and 25 U
BamHI for CYP2C19m2. The digested PCR products
were analyzed on 3% agarose gels and stained with
ethidium bromide.
Numerical data are given as the mean ± standard
deviation. Statistical differences in mean age, body
weight, ratio of gastric to duodenal ulcers, and cure
rates for H. pylori infection among the genotype groups
were determined by using one-way analysis of variance
and Fisher’s exact test. A p value of < 0.05 was consid-
ered statistically significant.
Results
All patients completed the study according to the
protocol. Their clinical characteristics are presented in
Table 1. Adherence to the prescribed medication reg-
imen was 100% in 42 patients, about 90% in 38 patients,
and about 75% in 15 patients. H. pylori was eradicated
in 100%, 86% and 80% of patients whose adherence was
100%, 90% and 75%, respectively.
Five different combination patterns were noted in
the 95 patients. Forty-two were homozygous for the
wt alleles (rapid-metabolizer group) in both exon 5
and exon 4 (wt/wt); 20 were heterozygous for the
CYP2C19m1 mutation without the CYP2C19m2
Table 1. Clinical characteristics*
Group 1 (n = 42) Group 2 (n = 38) Group 3 (n = 15) p
Age (yr) 49.5 ± 5.5 46.8 ± 4.8 48.7 ± 6.3 NS
Sex (M/F) 32/10 29/9 10/5 NS
Etiology NS
Alcoholism 11 (26) 10 (26) 3 (20) NS
Viral hepatitis 28 (66) 25 (65) 11 (73) NS
Others† 3 (7) 3 (8) 1 (6) NS
Child–Pugh class NS
A 29 (69) 26 (66) 11 (73) NS
B 10 (23) 9 (25) 3 (20) NS
C 3 (7) 3 (8) 1 (6) NS
Child–Pugh score 8.3 ± 1.6 8.2 ± 1.7 8.1 ± 1.8 NS
Prothrombin time (sec) 20.3 ± 4.5 21.4 ± 4.7 21.2 ± 4.6 NS
Albumin (g/dL) 2.8 ± 0.6 2.9 ± 0.8 2.8 ± 0.7 NS
Bilirubin (mg/dL) 2.7 ± 2.1 2.8 ± 2.2 2.7 ± 2.0 NS
Hemoglobin (g/dL) 8.7 ± 2.7 8.9 ± 2.8 8.8 ± 2.6 NS
Ascites present 6 (14) 5 (13) 2 (13) NS
Serum alanine transferase (U/L) 105 ± 60 110 ± 58 114 ± 7.2 NS
Follow-up period (mo)‡ 35.4 ± 19.6 34.8 ± 18.8 35.2 ± 19.2 NS
*Data are presented as mean ± standard deviation or n or n (%); †includes primary biliary cirrhosis and cryptogenic cirrhosis; ‡only those who were followed
for > 30 days are included. NS = not significant.
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mutation (wt/CYP2C19m1); 18 were heterozygous for
the CYP2C19m2 mutation without CYP2C19m1 mu-
tation (wt/CYP2C19m2); 20 were heterozygous for
the CYP2C19m1 mutation and the CYP2C19m2 mu-
tation (CYP2C19m1/CYP2C19m2); and 35 were ho-
mozygous for the CYP2C19m1 mutation without the
CYP2C19m2 mutation (CYP2C19m1/CYP2C19m1).
All patients were arbitrarily classified into 3 genotype
groups: group 1 was the non-mutation group (wt/
wt) (n = 42); group 2 was the 1-mutation group (wt/
CYP2C19m1 or wt/CYP2C19m2) (n = 38); and
group 3 was the 2-mutation group (CYP2C19m1/
CYP2C19m1 or CYP2C19m1/CYP2C19m2) (n=15)
(Table 2). The CYP2C19 phenotypes of groups 1, 2
and 3 corresponded to the rapid-extensive, interme-
diate-extensive, and poor-metabolizer phenotypes of
CYP2C19, respectively.
H. pylori infection was cured in 86 of the 95
patients [90.5%; 95% confidence interval (CI), 22.7–
87.5%]. The cure rates of H. pylori infection for the 
3 genotype groups are shown in Table 3. The cure
rate was highest in group 3, intermediate in group 2,
and lowest in group 1. Ulcer healing was achieved in
40 of the 48 patients with cirrhosis and gastric ulcer,
and 41 of the 47 with duodenal ulcer. In patients in
whom H. pylori infection was cured, all ulcer lesions
were healed at follow-up endoscopic examination.
Ulcer healing rates for patients with cirrhosis and gas-
tric ulcer in groups 1, 2 and 3 were 80% (95% 
CI, 38.9–85.6%) (16 of 20 patients), 90% (95% CI,
69.9–99.8%) (18 of 20 patients), and 100% (95% CI,
70.8–100.0%) (all 8 patients), respectively. Ulcer
healing rates for patients with cirrhosis and duodenal
ulcer were 81.8% (95% CI, 36.8–97.6%) (18 of 
22 patients), 88.8% (95% CI, 62.6–98.8%) (16 of 
18 patients), and 100% (95% CI, 75.8–100.0%) (all 
7 patients), respectively.
Discussion
Hepatic drug oxidation is a major cause of interindi-
vidual variations in pharmacokinetics and therapeutic
response. The expression of individual P450 proteins
in the liver is influenced by a number of factors such
as genetic make-up, disease, aging, and environmental
factors (smoking, alcohol, nutrition and pollutants).
As the metabolism of proton pump inhibitors is mainly
catalyzed by CYP2C19 and CYP3A4,22 genetic poly-
morphism of CYP2C19 could be of clinical concern
in the treatment of acid-related diseases with proton
pump inhibitors.14
Oxidation shows considerable interethnic differ-
ence; 2–6% of Caucasians and 1% of African–Americans
Table 2. Demographic and clinical characteristics of 95 patients with cirrhosis and peptic ulcer in 3 genotype groups
Variable Group 1 (n = 42) Group 2 (n = 38) Group 3 (n = 15) p
CYP2C19 (status) wt/wt wt/m1* or wt/m2† m1/m2‡ or m1/m1§
Mean age ± SD (yr) 49.5 ± 5.5 46.8 ± 4.8 48.7 ± 6.3 NS
Mean weight ± SD (kg) 65.7 ± 7.9 63.6 ± 5.9 64.8 ± 8.6 NS
Gastric ulcer/duodenal ulcer (n/n) 20/22 20/18 8/7 NS
*Heterozygous for CYP2C19m1 without CYP2C19m2; †heterozygous for CYP2C19m2 without CYP2C19m1; ‡heterozygous for CYP2C19m1 and CYP2C19m2;
§homozygous for CYP2C19m1 without CYP2C19m2. m1 = CYP2C19 mutation in exon5; m2 = CYP2C19 mutation in exon 4; wt = wild-type; NS = not significant.
Table 3. Cure rates of Helicobacter pylori infection in 3 genotype groups*
Cure rate of H. pylori infection (95% CI)
Type of ulcer Group 1 (n = 42) Group 2 (n = 38) Group 3 (n = 15) p
% (n/n)
Gastric ulcer† 80.0 (16/20) 90.0 (18/20) 100 (8/8) < 0.05
Duodenal ulcer‡ 81.8 (18/22) 88.8 (16/18) 100 (7/7) < 0.05
Total§ 80.9 (34/42) 89.8 (34/38) 100 (15/15) < 0.001
*Group 1 was the non-mutation group, group 2 was the 1-mutation group, and group 3 was the 2-mutation group; †p < 0.05 for group 1 compared with 
group 2, p < 0.05 for group 1 compared with group 3, p < 0.05 for group 2 compared with group 3 (Fisher’s exact test); ‡p < 0.05 for group 1 compared 
with group 2, p < 0.05 for group 1 compared with group 3, p < 0.05 for group 2 compared with group 3 (Fisher’s exact text); §p < 0.05 for group 1 compared
with group 2, p < 0.05 for group 1 compared with group 3, p < 0.05 for group 2 compared with group 3 (Fisher’s exact test). CI = confidence interval.
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have been identified as carrying the PM phenotype,
whereas its frequency is 19–23% in Japanese, 15% in
Chinese and 13% in Koreans.23 This defect (referred
to as CYP2C19m1) is common in Asian and Caucasian
populations.21
Our study shows that rates of cure of H. pylori
infection in our patients depended on CYP2C19 geno-
type patterns. In the poor-metabolizer group (patients
with CYP2C19m1/CYP2C19m1 or CYP2C19m1/
CYP2C19m2), triple therapy with 20 mg rabeprazole,
1,000 mg clarithromycin and 2,000 mg amoxicillin for
2 weeks seemed to be fully effective in curing H. pylori
infection.
There are several reasons why triple therapy achieves
greater success in curing H. pylori infection in patients
with the poor-metabolizer genotype (group 3) than in
those with the extensive-metabolizer genotypes (groups
1 and 2). First, because the metabolic disposition of
rabeprazole is genetically determined by CYP2C19
enzyme activity, the plasma concentration–time curve
of rabeprazole (that is, the systemic availability of the
drug in the circulation) is markedly increased in persons
with the poor-metabolizer phenotype or genotype of
CYP2C19.17,22 Consequently, the duration of high
intragastric pH levels is longer in patients with the poor-
metabolizer genotype than in those with the extensive-
metabolizer genotypes. Second, because amoxicillin is
unstable and its antibacterial activity is decreased under
low pH conditions, increasing the intragastric pH to
neutral levels by H. pylori infection, and an increased
acid-inhibitory effect of rabeprazole, could contribute
to the excellent ulcer healing rates seen in patients with
the poor-metabolizer genotype of CYP2C19, who had
either gastric or duodenal ulcer disease. Substantial eth-
nic differences have been reported in the incidence of
the poor-metabolizer genotype, much lower (3–5%)
in white American or European populations than in
Japanese (18–23%).24–26 Thus, it seems reasonable
that triple therapy with rabeprazole (20–40 mg/day)
and amoxicillin (2,000 mg/day) has generally not
achieved adequate cure rates for H. pylori infection
and ulcer disease in these American and European
populations.22 However, some authors have reported
that dual therapy with high doses of omeprazole (40mg
3 times daily) and amoxicillin (750 mg 3 times daily)
could achieve a cure rate of 91% in these populations,
even though most of the patients probably had exten-
sive metabolizer genotypes.21,22
Recently, many studies have been reported in
patients with cirrhosis and H. pylori infection.27–35 It
has been demonstrated that the eradication rate or
CYP2C19 polymorphisms are different in patients
with cirrhosis and peptic ulcer disease, compared with
those without cirrhosis.30–32 However, our results must
be interpreted within the context of the limitations of
our study. First, we did not measure plasma rabeprazole
levels and were therefore unable to correlate directly
H. pylori infection and ulcer cure rates with plasma
drug availability. Second, our sample size was small.26
Therefore, our findings must be considered prelimi-
nary; further study is required in larger groups of
patients with cirrhosis, and should include measure-
ment of plasma rabeprazole concentrations. Further-
more, the clinical usefulness and cost-effectiveness of
genotyping as a clinical tool in the management of 
H. pylori-associated gastrointestinal disease remain to be
determined.11 Thus, further study is needed to inves-
tigate the real correlation of CYP2C19 genotype with
eradication of H. pylori infection in patients with cir-
rhosis and peptic ulcer.
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